The Myasthenia Gravis Foundation of America (MGFA) has published a new resource designed to help people with myasthenia gravis (MG) understand the medical jargon and terminology that’s commonly used to discuss the disease. The MG Lexicon offers succinct definitions for a wide range of terms. The definitions…
News
Blood levels of five proteins involved in the body’s inflammatory response may be used to diagnose myasthenia gravis (MG) and distinguish it from other autoimmune diseases, according to new research findings from scientists working in Sweden and Germany. The research team also identified other small sets of inflammatory proteins…
Imaavy (nipocalimab) has been approved in the European Union as an add-on to standard of care treatment for adults and adolescents, ages 12 and older, with generalized myasthenia gravis (gMG) and self-reactive antibodies targeting the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK). The decision by the European Commission makes…
An enzyme, called S-1117, can disarm self-reactive immunoglobulin G (IgG) antibodies targeting the acetylcholine receptor (AChR) that drive most cases of myasthenia gravis (MG), according to a study that used blood samples from patients. “This study presents S-1117, an IgG-specific protease [a protein-degrading enzyme], as a promising therapeutic approach…
Note: This story was updated Nov. 26, 2025, to correct that the cladribine formulation being tested as a potential gMG treatment differs from the one used in Mavenclad, an approved therapy for multiple sclerosis. The U.S. Food and Drug Administration (FDA) has granted fast track designation to cladribine, an…
In Japan, myasthenia gravis (MG) was associated with an older age at onset and better clinical outcomes in 2018 compared with 2006, according to a new analysis of nationwide survey data spanning 12 years. Data also showed a reduction over time in the doses of corticosteroids, anti-inflammatory steroid…
The first patient has been enrolled in a myasthenia gravis (MG) registry to collect clinical information from real-world settings across the U.S., with the aim of better understanding the disease and ultimately improving care. Thermo Fisher Scientific’s newly launched registry is recruiting people with the ocular and generalized…
Results from an ongoing Phase 1/2 clinical trial testing Cabaletta Bio‘s experimental cell therapy rese-cel (resecabtagene autoleucel) in adults with myasthenia gravis (MG) are expected in the second half of 2026. That’s according to a press release from Cabaletta, where the company reported its latest financial and…
Fifteen college or trade school scholarships are now available for people with myasthenia gravis (MG) and their immediate family members through the second annual UCB U.S. Myasthenia Gravis Scholarship program. The scholarships, worth up to $10,000, will help ease the financial burden of continuing education or career training…
A single dose of KYV-101, a cell therapy being developed by Kyverna Therapeutics for generalized myasthenia gravis (gMG), led to rapid and sustained reductions in symptom severity — lasting up to six months thus far — in adults with gMG. That’s according to data from an interim…
Recent Posts
- Grieving the loss of independence after an MG diagnosis
- How I’m able to continue teaching while living with myasthenia gravis
- Benefits of statins may outweigh risks for many living with MG
- Problems with disturbed sleep affect 2 in 3 people with stable MG: Study
- Distinct immune profile found in treatment-resistant myasthenia gravis